Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-09-2020 | Prostate Cancer | Original Article – Clinical Oncology

Feasibility and safety of 1.5 T MR-guided and daily adapted abdominal-pelvic SBRT for elderly cancer patients: geriatric assessment tools and preliminary patient-reported outcomes

Authors: Rosario Mazzola, Vanessa Figlia, Michele Rigo, Francesco Cuccia, Francesco Ricchetti, Niccolò Giaj-Levra, Luca Nicosia, Claudio Vitale, Gianluisa Sicignano, Antonio De Simone, Stefania Naccarato, Ruggero Ruggieri, Filippo Alongi

Published in: Journal of Cancer Research and Clinical Oncology | Issue 9/2020

Abstract

Background

We present preliminary data of the first older cancer patients treated with Hybrid Linac for stereotactic body radiotherapy (SBRT) consisting of 1.5 T MRI-guided and daily-adapted treatment. The aim was to assess feasibility, safety and the role of G8 and Charlson Comorbidity Index (CCI) questionnaires in predicting patients’ QoL, evaluated by patient-reported outcome measures (PROMs).

Methods

Two groups of patients with localized prostate cancer or abdominal-pelvic oligometastases were analyzed. SBRT schedule consisted of 35 Gy delivered in 5 fractions. The primary endpoint was to measure the impact of G8 and CCI on PROMs. Both G8 and the CCI were performed at baseline, while the EORTC Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) for PROMs assessment was prospectively performed at baseline and after SBRT.

Results

Forty older patients were analyzed. The median age was 73 years (range 65–85). For the entire population, the median G8 score was 15 (10–17) and the median CCI score was 6 (4–11). Concerning the PROMS, the EORTC-QLQ C30 questionnaire reported no difference between the pre- and post-SBRT evaluation in all patients, except for the fatigue item that declined after SBRT, especially in the group of patients with a G8 score < 15 and with age < 75 years (p = 0.049). No grade 3 or higher acute toxicity occurred.

Conclusion

This is the first report documenting for older cancer patients that 1.5 T MRI-guided daily-adapted SBRT is feasible, safe and does not impact on the QoL at the end of treatment. Longer follow-up is advocated to report long-term outcomes.

Trial registration

Date of approval April 2019 and numbered MRI/LINAC no. 23748.

Available only for authorised users

Alongi F, Fiorentino A, Mancosu P, Navarria P, Giaj Levra N, Mazzola R et al (2016) Stereotactic radiosurgery for intracranial metastases: Linac-based and gamma-dedicated unit approach. Expert Rev Anticancer Ther 16(7):731–740CrossRef

Alongi F, Mazzola R, Fiorentino A, Corradini S, Aiello D, Figlia V et al (2019) Phase II study of accelerated Linac-based SBRT in five consecutive fractions for localized prostate cancer. Strahlenther Onkol 195(2):113–120. https://doi.org/10.1007/s00066-018-1338-7 CrossRefPubMed

De Bari B, Alongi F, Mortellaro G, Mazzola R, Schiappacasse L, Guckenberger M (2016) Spinal metastases: Is stereotactic body radiation therapy supported by evidences? Crit Rev Oncol Hematol 98:147–158CrossRef

De Bari B, Arcangeli S, Ciardo D, Mazzola R, Alongi F, Russi EG, Santoni R, Magrini SM, Jereczek-Fossa BA, on the behalf of the Italian Association of Radiation Oncology (AIRO) (2016) Extreme hypofractionation for early prostate cancer: biology meets technology. Cancer Treat Rev 50:48–60CrossRef

Birim O, Kappetein AP, Bogers AJ (2005) Charlson comorbidity index as a predictor of long-term outcome after surgery for non-small cell lung cancer. Eur J Cardiothorac Surg 28(5):759–762CrossRef

Chargari C, Moriceau G, Auberdiac P, Guy JB, Assouline A, Tinquaut F, Falk AT, Eddekkaoui H, Bourmaud A, Coscas Y, Annede P, Rivoirard R, Mery B, Trone JC, Otmezguine Y, Pacaut C, Bauduceau O, Vedrine L, Merrouche Y, Magne N (2014) Feasibility of radiation therapy in patients 90years of age and older: a French multicentre analysis. Eur J Cancer 50(8):1490–1497. https://doi.org/10.1016/j.ejca.2014.02.012 CrossRefPubMed

Chiumento C, Fiorentino A, Cozzolino M, Caivano R, Clemente S, Pedicini P, Fusco V (2013) Impact of comorbidity in elderly prostate cancer patients treated with brachytherapy. Chin J Cancer Res 25(3):274–280. https://doi.org/10.3978/j.issn.1000-9604.2013.06.06 CrossRefPubMedPubMedCentral

Corradini S, Alongi F, Andratschke N, Belka C, Boldrini L, Cellini F et al (2019) MR-guidance in clinical reality: current treatment challenges and future perspectives. Radiat Oncol 14(1):92. https://doi.org/10.1186/s13014-019-1308-y CrossRefPubMedPubMedCentral

Cuccia F, Fiorentino A, Corrao S, Mortellaro G, Valenti V, Tripoli A, De Gregorio G, Serretta V, Verderame F, Ognibene L, Lo Casto A, Ferrera G (2019) Moderate hypofractionated helical tomotherapy for prostate cancer in a cohort of older patients: a mono-institutional report of toxicity and clinical outcomes. Aging Clin Exp Res. https://doi.org/10.1007/s40520-019-01243-1 CrossRefPubMed

Cuccia F, Mortellaro G, Mazzola R, Donofrio A, Valenti V, Tripoli A, Matranga D, Lo Casto A, Failla G, Di Miceli G, Ferrera G (2019) Prognostic value of two geriatric screening tools in a cohort of older patients with early stage non-small cell lung cancer treated with hypofractionated stereotactic radiotherapy. J Geriatr Oncol. https://doi.org/10.1016/j.jgo.2019.05.002 CrossRefPubMed

DeWees TA, Nikitas J, Rehman S, Bradley JD, Robinson CG, Roach MC (2018) Defining optimal comorbidity measures for patients with early stage non-small cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT). Pract Radiat Oncol. https://doi.org/10.1016/j.prro.2018.09.001 CrossRefPubMedPubMedCentral

Dewey M, Schink T, Dewey CF (2007) Claustrophobia during magnetic resonance imaging: Cohort study in over 55,000 patients. J Magn Reson Imaging 26(5):1322–1327CrossRef

Donovan JL, Hamdy FC, Lane JA, Mason M, Metcalfe C, Walsh E et al (2016) Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 375(15):1425–1437. https://doi.org/10.1056/NEJMoa1606221 CrossRefPubMedPubMedCentral

Droz JP, Albrand G, Gillessen S, Hughes S, Mottet N, Oudard S, Payne H, Puts M, Zulian G, Balducci L et al (2017) Management of prostate cancer in elderly patients: Recommendations of a task force of the international society of geriatric oncology. Eur Urol 72:521–531. https://doi.org/10.1016/j.eururo.2016.12.025 CrossRefPubMed

Fiorentino A, Ricchetti F, Mazzola R, Fersino S, Giaj Levra N, Alongi F, Regarding E et al (2015) Charlson comorbidity index: an additional prognostic parameter for preoperative glioblastoma patient stratification. J Cancer Res Clin Oncol. 141(6):1139–1140CrossRef

Fiorentino A, Mazzola R, Giaj Levra N, Fersino S, Ricchetti F, Di Paola G et al (2018) Comorbidities and intensity-modulated radiotherapy with simultaneous integrated boost in elderly breast cancer patients. Aging Clin Exp Res 30(5):533–538CrossRef

Fiorentino A, Gregucci F, Mazzola R, Figlia V, Ricchetti F, Sicignano G et al (2019) Intensity-modulated radiotherapy and hypofractionated volumetric modulated arc therapy for elderly patients with breast cancer: comparison of acute and late toxicities. Radiol Med 124(4):309–314CrossRef

Fiorentino A, Gregucci F, Mazzola R, Figlia V, Ricchetti F, Sicignano G, Giaj Levra N, Ruggieri R, Fersino S, Naccarato S, Massocco A, Corradini S, Alongi F (2019) Intensity-modulated radiotherapy and hypofractionated volumetric modulated arc therapy for elderly patients with breast cancer: comparison of acute and late toxicities. Radiol Med 124(4):309–314. https://doi.org/10.1007/s11547-018-0976-2 CrossRefPubMed

Fiorino C, Guckemberger M, Schwarz M, van der Heide UA, Heijmen B (2020) Technology-driven research for radiotherapy innovation. Mol Oncol. https://doi.org/10.1002/1878-0261.12659 CrossRefPubMedPubMedCentral

Goineau A, Campion L, d'Aillières B, Vié B, Ghesquière A, Béra G, Jaffres D, de Laroche G, Magné N, Artignan X, Chamois J, Bergerot P, Martin E, Créhange G, Deniaud-Alexandre E, Buthaud X, Belkacémi Y, Doré M, de Decker L, Supiot S (2018) Comprehensive Geriatric Assessment and quality of life after localized prostate cancer radiotherapy in elderly patients. PLoS ONE 13(4):e0194173. https://doi.org/10.1371/journal.pone.0194173 CrossRefPubMedPubMedCentral

Hui R, Özgüroğlu M, Villegas A, Daniel D, Vicente D, Murakami S, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Gray JE, Rydén A, Viviers L, Poole L, Zhang Y, Dennis PA, Antonia SJ (2019) Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study. Lancet Oncol 20(12):1670–1680. https://doi.org/10.1016/S1470-2045(19)30519-4 CrossRefPubMed

Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP et al (2011) Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 29(25):3457–3465. https://doi.org/10.1200/JCO.2011.34.7625 CrossRefPubMedPubMedCentral

Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS (1999) Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341(27):2061–2067CrossRef

Kenis C, Decoster L, Van Puyvelde K, De Grève J, Conings G, Milisen K et al (2014) Performance of two geriatric screening tools in older patients with cancer. J Clin Oncol 32(1):19–26. https://doi.org/10.1200/JCO.2013.51.1345 CrossRefPubMed

Khor RC, Bressel M, Tedesco J, Tai KH, Ball DL, Duchesne GM, Farrugia H, Yip WK, Foroudi F (2015) Tolerability and outcomes of curative radiotherapy in patients aged 85 or more years. Med J Aust 202(3):153–155CrossRef

Kopek N, Paludan M, Petersen J, Hansen AT, Grau C, Høyer M (2009) Co-morbidity index predicts for mortality after stereotactic body radiotherapy for medically inoperable early-stage non-small cell lung cancer. Radiother Oncol 93(3):402–407. https://doi.org/10.1016/j.radonc.2009.06.002 CrossRefPubMed

Kreinbrink P, Blumenfeld P, Tolekidis G, Sen N, Sher D, Marwaha G (2017) Lung stereotactic body radiation therapy (SBRT) for early-stage non-small cell lung cancer in the very elderly (≥ 80years old): extremely safe and effective. J Geriatr Oncol 8(5):351–355. https://doi.org/10.1016/j.jgo.2017.07.002 CrossRefPubMed

Lipsett A, Barrett S, Haruna F, Mustian K, O'Donovan A. The impact of exercise during adjuvant radiotherapy for breast cancer on fatigue and quality of life: A systematic review and meta-analysis. Breast. 2017;32:144-155;

Liuu E, Canoui-Poitrine F, Tournigand C et al (2014) Accuracy of the G-8geriatric-oncology screening tool for identifying vulnerable elderly patients with cancer according to tumour site: the ELCAPA-02 study. J Geriatr Oncol 5:11–19. https://doi.org/10.1016/j.jgo.2013.08.003 CrossRefPubMed

Maebayashi T, Ishibashi N, Aizawa T, Sakaguchi M, Saito T, Kawamori J et al (2018) Significance of stereotactic body radiotherapy in older patients with early stage non-small cell lung cancer. J Geriatr Oncol 9(6):594–599. https://doi.org/10.1016/j.jgo.2018.03.005 CrossRefPubMed

Narayanan V, Koshy C (2009) Fatigue in cancer: a review of literature. Indian J Palliat Care 15(1):19–25CrossRef

O'Donovan A, Leech M, Gillham C (2017) Assessment and management of radiotherapy induced toxicity in older patients. J Geriatr Oncol 8(6):421–427. https://doi.org/10.1016/j.jgo.2017.07.001 CrossRefPubMed

Padhani AR, Liu G, Koh DM, Chenevert TL, Thoeny HC, Takahara T et al (2009) Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 11(2):102–125CrossRef

Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, et al (2017) Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28(suppl_4):iv1–iv21. https://doi.org/10.1093/annonc/mdx222

Pottel L, Lycke M, Boterberg T, Pottel H, Goethals L, Duprez F et al (2015) G-8 indicates overall and quality-adjusted survival in older head and neck cancer patients treated with curative radiochemotherapy. BMC Cancer 9(15):875. https://doi.org/10.1186/s12885-015-1800-1 CrossRef

Radovic M, Kanesvaran R, Rittmeyer A, Früh M, Minervini F, Glatzer M et al (2018) Multidisciplinary treatment of lung cancer in older patients: a review. J Geriatr Oncol. https://doi.org/10.1016/j.jgo.2018.09.005 CrossRefPubMed

Ruggieri R, Naccarato S, Stavrev P, Stavreva N, Fersino S, Giaj Levra N, Mazzola R, Mancosu P, Scorsetti M, Alongi F (2015) Volumetric-modulated arc stereotactic body radiotherapy for prostate cancer: dosimetric impact of an increased near-maximum target dose and of a rectal spacer. Br J Radiol 88(1054):20140736CrossRef

Triggiani L, Alongi F, Buglione M, Detti B, Santoni R, Bruni A, Maranzano E, Lohr F, D'Angelillo R, Magli A, Bonetta A, Mazzola R, Pasinetti N, Francolini G, Ingrosso G, Trippa F, Fersino S, Borghetti P, Ghirardelli P, Magrini SM (2017) Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study. Br J Cancer 116(12):1520–1525CrossRef

Triggiani L, Mazzola R, Magrini SM, Ingrosso G, Borghetti P, Trippa F, Lancia A, Detti B, Francolini G, Matrone F, Bortolus R, Fanetti G, Maranzano E, Pasqualetti F, Paiar F, Bonù ML, Magli A, Bruni A, Mazzeo E, Franzese C, Scorsetti M, Alongi F, Jereczek-Fossa BA, Ost P, Buglione M (2019) Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study. World J Urol 37(12):2631–2637CrossRef

Videtic GMM, Woody NM, Reddy CA, Stephans KL (2017) Never too old: A single-institution experience of stereotactic body radiation therapy for patients 90 years and older with early stage lung cancer. Pract Radiat Oncol 7(6):e543–e549. https://doi.org/10.1016/j.prro.2017.06.011 CrossRefPubMed

Wang XS, Woodruff JF (2015) Cancer-related and treatment-related fatigue. Gynecol Oncol 136(3):446–452CrossRef

Winkel D, Bol GH, Kroon PS, van Asselen B, Hackett SS, Werensteijn-Honingh AM et al (2019) Adaptive radiotherapy: the Elekta Unity MR-Linac concept. Clin Transl Radiat Oncol 18:54–59. https://doi.org/10.1016/j.ctro.2019.04.001 CrossRefPubMedPubMedCentral

Title: Feasibility and safety of 1.5 T MR-guided and daily adapted abdominal-pelvic SBRT for elderly cancer patients: geriatric assessment tools and preliminary patient-reported outcomes
Authors: Rosario Mazzola
Vanessa Figlia
Michele Rigo
Francesco Cuccia
Francesco Ricchetti
Niccolò Giaj-Levra
Luca Nicosia
Claudio Vitale
Gianluisa Sicignano
Antonio De Simone
Stefania Naccarato
Ruggero Ruggieri
Filippo Alongi
Publication date: 01-09-2020
Publisher: Springer Berlin Heidelberg
Keywords: Prostate Cancer
Prostate Cancer
Radiotherapy
Fatigue
Published in: Journal of Cancer Research and Clinical Oncology / Issue 9/2020
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-020-03230-w

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Feasibility and safety of 1.5 T MR-guided and daily adapted abdominal-pelvic SBRT for elderly cancer patients: geriatric assessment tools and preliminary patient-reported outcomes

Abstract

Background

Methods

Results

Conclusion

Trial registration

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Trial registration

Please log in to get access to this content

Other articles of this Issue 9/2020

Targeted deep sequencing helps distinguish independent primary tumors from intrapulmonary metastasis for lung cancer diagnosis

Targeting glycolysis with 2-deoxy-d-glucose sensitizes primary cell cultures of renal cell carcinoma to tyrosine kinase inhibitors

Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity

Bone marrow adipocytes enhance osteolytic bone destruction by activating 1q21.3(S100A7/8/9-IL6R)-TLR4 pathway in lung cancer

Lymphocyte activation gene-3 (LAG3) mRNA and protein expression on tumour infiltrating lymphocytes (TILs) in oesophageal adenocarcinoma

MYC/BCL2/BCL6 triple hit lymphoma of the pericardium: a case report and review of the literature

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page